Summary

Translationally relevant preclinical models are critical for MASH drug development, yet many fail to fully capture the complex metabolic and hepatic features of human disease. This whitepaper presents BioDuro’s HFD-induced MASH mouse model, highlighting its ability to reproduce key disease characteristics and demonstrate consistent responses to clinically relevant therapies. The model offers a practical, reproducible platform for robust efficacy assessment, enabling faster, more confident decisions from early screening to late‑stage validation.

• High translational relevance: Recapitulates key metabolic and pathological features associated with human MASH
• Clinically validated: Demonstrates consistent responses to therapies with distinct mechanisms of action
• Comprehensive assessment: Supports evaluation across metabolic, biochemical, and histopathological endpoints
• Study-ready model: Offers reproducible disease phenotypes and ready-to-use animals to streamline preclinical studies

Download the full whitepaper to see how this clinically validated model can de‑risk your MASH program and accelerate path to the clinic.